Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes

Diabetes

Volumn 65, Issue 1, 2016, Pages 216-227

  Zampetaki, Anna ^a   Willeit, Peter ^a,b,c   Burr, Simon ^a   Yin, Xiaoke ^a   Langley, Sarah R ^a   Kiechl, Stefan ^c   Klein, Ronald ^d   Rossing, Peter ^e   Chaturvedi, Nishi ^f   Mayr, Manuel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; MICRORNA; MICRORNA 27B; MICRORNA 320A; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN27 MICRORNA, HUMAN; MIRN320 MICRORNA, HUMAN;

ADULT; ANGIOGENESIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN TARGETING; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; UMBILICAL VEIN ENDOTHELIAL CELL; COHORT ANALYSIS; COMPLICATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); ODDS RATIO; SECRETION (PROCESS); STATISTICAL MODEL; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; ODDS RATIO; PROTEOMICS; RNA, MESSENGER; THROMBOSPONDIN 1; YOUNG ADULT;

EID: 84962203774     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0389     Document Type: Article

References (46)

1. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res 2012;110:508-522
2. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012;11:860-872
3. Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: the microRNA perspective. Diabetes 2011;60:1832-1837
4. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-817
5. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012;60:290-299
6. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013;112:595-600
7. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012; 93:555-562
8. Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol 2013;33:206-214
9. Chaturvedi N, Porta M, Klein R, et al.; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-1402
10. Yin X, Bern M, Xing Q, Ho J, Viner R, Mayr M. Glycoproteomic analysis of the secretome of human endothelial cells. Mol Cell Proteomics 2013;12:956-978
11. Abonnenc M, Nabeebaccus AA, Mayr U, et al. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ Res 2013; 113:1138-1147
12. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558
13. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J 2010;52:70-84
14. Dhanabal M, Wu F, Alvarez E, et al. Recombinant semaphorin 6A-1 ecto-domain inhibits in vivo growth factor and tumor cell line-induced angiogenesis. Cancer Biol Ther 2005;4:659-668
15. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14: 2532-2539
16. Zampetaki A, Attia R, Mayr U, et al. Role of miR-195 in aortic aneurysmal disease. Circ Res 2014;115:857-866
17. Wang JM, Tao J, Chen DD, et al. MicroRNA miR-27b rescues bone marrow-derived angiogenic cell function and accelerates wound healing in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2014;34:99-109
18. Karolina DS, Tavintharan S, Armugam A, et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 2012;97:E2271-E2276
19. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 2015;64:631-642
20. van Hecke MV, Dekker JM, Stehouwer CD, et al.; EURODIAB Prospective Complications Study. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB Prospective Complications Study. Diabetes Care 2005;28:1383-1389
21. Kovacs B, Lumayag S, Cowan C, Xu S. MicroRNAs in early diabetic reti-nopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2011; 52:4402-4409
22. Feng B, Chen S, McArthur K, et al. miR-146a-mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 2011;60:2975-2984
23. Silva VA, Polesskaya A, Sousa TA, et al. Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats. Mol Vis 2011;17: 2228-2240
24. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic reti-nopathy. Diabetes 2011;60:1314-1323
25. Murray AR, Chen Q, Takahashi Y, Zhou KK, Park K, Ma JX. MicroRNA-200b downregulates oxidation resistance 1 (Oxr1) expression in the retina of type 1 diabetes model. Invest Ophthalmol Vis Sci 2013;54:1689-1697
26. Bai Y, Bai X, Wang Z, Zhang X, Ruan C, Miao J. MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. Exp Mol Pathol 2011;91:471-477
27. Ling S, Birnbaum Y, Nanhwan MK, Thomas B, Bajaj M, Ye Y. MicroRNA-dependent cross-talk between VEGF and HIF1a in the diabetic retina. Cell Signal 2013;25:2840-2847
28. Tang H, Lee M, Sharpe O, et al. Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems. FASEB J 2012;26:4710-4721
29. Wang X, Huang W, Liu G, et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol 2014;74:139-150
30. Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC, Hong TM. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis 2014;17:247-260
31. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007;101:59-68
32. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23;27;24 clusters. Proc Natl Acad Sci U S A 2011;108: 8287-8292
33. Urbich C, Kaluza D, Frömel T, et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 2012;119: 1607-1616
34. Biyashev D, Veliceasa D, Topczewski J, et al. miR-27b controls venous specification and tip cell fate. Blood 2012;119:2679-2687
35. Stenina-Adognravi O. Thrombospondins: old players, new games. Curr Opin Lipidol 2013;24:401-409
36. Tolsma SS, Stack MS, Bouck N. Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1. Microvasc Res 1997;54:13-26
37. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285:38923-38932
38. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004;45: 1117-1124
39. Suzuma K, Takagi H, Otani A, Oh H, Honda Y. Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am J Pathol 1999;154:343-354
40. Kermorvant-Duchemin E, Sennlaub F, Sirinyan M, et al. Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med 2005;11:1339-1345
41. Choi J, Lin A, Shrier E, Lau LF, Grant MB, Chaqour B. Degradome products of the matricellular protein CCN1 as modulators of pathological angiogenesis in the retina. J Biol Chem 2013;288:23075-23089
42. Sorenson CM, Wang S, Gendron R, Paradis H, Sheibani N. Thrombospondin-1 deficiency exacerbates the pathogenesis of diabetic retinopathy. J Diabet Metabol S12:005 doi: 10.4172/2155-6156.S12-005
43. Ii M, Takenaka H, Asai J, et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res 2006;98:697-704
44. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
45. Levey AS, Coresh J, Greene T, et al.; Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum cre-atinine values. Clin Chem 2007;53:766-772
46. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000;49: 626-632